Background: Hyperactivity disorder and attention deficit are common neurological
have not shown the risk of developing a polygenic disorder for ADHD in their childhood. The findings have shown that adults with ADHD symptoms may not have a childhood neurological disease (Moffitt et al., 2015) . In adulthood, attention deficit and hyperactivity symptoms become more and less pronounced, respectively. Unfavorable factors such as imprisonment of father, parental psychiatric illness, occupational stress, and being under 0custody of foster parents increase the risk of ADHD in adolescent (Katz-Bearnot, 2009 ).
Perinatal complications, which occur in preterm delivery and early delivery, are the most important factors related to the diagnosis of ADHD (Serati, Barkin, Orsenigo, Altamura, & Buoli, 2017) .
Patients with this disorder may have cognitive, emotional and behavioural difficulties, such as opium abuse (Fergusson & Boden, 2008; Upadhyaya, 2007) , high-risk sexual behaviors (Barkley, Fischer, Edelbrock, & Smallish, 1990) , increased incidence of severe crashes and trauma (Barkley et al., 1990; Kaya et al., 2008) , Internet addiction (Ko, Yen, Chen, Chen, & Yen, 2008) , and job and educational problems (Sadock, 2009; Upadhyaya, 2007; Wender, 1998) . Other features of ADHD in adulthood include mood instability, antisocial behavior, alcohol abuse, risk factor for anxiety disorders, mood (bipolar disorder and major depressive disorder), and personality disorders (Asherson, 2005; Philipsen et al., 2008) . ADHD in workers causes many disturbances in their work. In most cases, this disorder is not cured and so imposes a high cost to the community (de Graaf et al., 2008; Kessler, Lane, Stang, & Van Brunt, 2009 ).
Norepinephrine and dopamine systems may be involved in the pathophysiology of ADHD. It seems that the cognitive regulation system of the brain is disordered due to inappropriate dopamine or norepinephrine function or impairment of their release in the synapse (Kessler et al., 2009 ). According to these neurotransmitter changes, central nervous system stimulants such as methylphenidate have been known as the selected drug for children with ADHD (Katz-Bearnot, 2009 ).
The main focus of treatment in adults with ADHD is still drug therapy. Drug treatment with stimulants, including methylphenidate, is associated with good response rates (up to 70%), but due to several reasons such as the need for multiple doses, their intolerable complications to the patient, the possibility of drug abuse, cardiovascular side effects, and occurrence of stigma due to their consumption, other pharmacological options may be needed, including desipramine, bupropion, atomoxtein, or venlafaxine (Amiri, Farhang, Ghoreishizadeh, Malek, & Mohammadzadeh, 2012; Fergusson & Boden, 2008; Sadock et al.,2009) . Memantine is a noncompetitive N-Methyl-D-Aspartate (NMDA) antagonist, which has low to moderate affinity. Memantine was first developed in the 1960s, and was used for treating dementia, brain diseases, and Parkinson's disease after a clinical trial in Germany in the late 1980s (Baldessarini, 1996) . Memantine has been approved by the FDA as an Alzheimer's treatment. During the clinical trials and studies, this drug was generally well tolerated and it was not complicated compared with placebo (Garfield, Getsios, Caro, Wimo, & Winblad, 2002; Reisberg et al., 2006) .
Failure of glutaminergic system in ADHD and excess of glutamate release in the prefrontal and striatum cortex from the intracellular space to synaptic space activate postsynaptic glutamate receptors, NMDA and AMPA, and kinat, and each of which intrudes with the process of neurodegenerative toxicity and cell death, resulting in learning and memory problems, and NMDA receptors have major role in this case, which causes cell death through high permeability of calcium ions. Thus, memantine has been introduced as a new drug treatment for ADHD. In some people, memantine is also recommended to improve performance impairment in ADHD patients (Carrey et al., 2003; Yu et al., 1997) .
Few studies have evaluated this drug as an ADHD treatment. Surman et al. (2013) referred to a single study that has been published in 2013 and showed that the adults and children who were treated with this drug had improvement and reduced the symptoms of the disease. However, there were no more consequences from the treatment of dementia in this group of patients (Surman et al., 2013 ).
Current does not provide enough support for its efficacy to advocate for its regular use in those conditions (Hosenbocus & Chahal, 2013) .
In some studies, off-label use of this drug is useful for the treatment of non-Alzheimer's disease (Zdanys & Tampi, 2008) . Another study conducted by Findling et al. (2007) suggested that the use of memantine with a dose of 2 to 20 mg for 8 weeks had useful effects on both aspects of the disease including hyperactivity and attention deficit (Findling et al., 2007) .
Considering the importance of treatment, the problems of adult ADHD patients, lack of therapeutic response, abuse of stimulant drugs, the availability of memantine in Iran, and regarding only few studies have been done about the effect of this drug on the treatment of ADHD disorder, this study was carried out to determine the effect of memantine on patients with ADHD. For examining the difference between the two groups and considering the probability of the first type error, 5% probability of the second type error was 2% of the sample size in each group.
| MATERIALS AND METHODS

This
| Method of study implementation
The study was a double-blind clinical trial (patient and physician were responsible for patient treatment, and no information was about the placement of patients in drug and placebo groups) that was performed in adult ADHD patients. Criteria for entering the study was age older than 18 and younger than 45, not taking any medication, which is effective on mental status, at least 2 weeks before the study, and confirmation of childhood ADHD was based on clinical interview.
Exclusion criteria were mental disability based on clinical interviews; presence of any other psychiatric disorder based on clinical interviews by a child and adolescent psychiatrist; substance or alcohol abuse (in a recent month); pregnant women; history of allergy to memantine; presence of a serious medical illness, such as heart disease, based on clinical interviews; uncontrolled seizure disorder based on clinical interviews; and individuals with a systolic blood pressure greater than 125 mmHg or resting pulse less than 60 or above 115 beats per minute, which were resulting in a severe side effect.
In this study, sample included 40 people. The participants of the current study were selected from parents of children diagnosed to have ADHD, because of high familial risk for ADHD (Sadock et al., 2009 ). In addition, other people who were recognized as adult ADHD in clinical interview were included in the study.
The samples were entered into the study after presenting the explanations about the stages of planning and obtaining written consent. First, the history of the presence of ADHD symptoms in their childhood was examined; if this was positive for the person, the Kiddie Schedule for Affective Disorders and Schizophrenia for School-Aged Children, Present and Lifetime Versions (K-SADS-PL), on childhood was completed, and if this information was confirmed by another person from the family of the child who is aware about his childhood, this person was selected, then the interview was conducted on all selected subjects based on the DSM-IV-TR criteria. A structured clinical interview was applied for DSM-IV disorders for excluding other psychiatric disorders.
Before treatment was started, the self-reporter of Conners' Screening Questionnaire (26 questions) was completed for each patient, and the subjects were entered the study after acquiring the minimum required score for this questionnaire. After collecting samples, the demographic information questionnaire was completed.
Study participants were randomly divided into two groups (1 and 2) and referred to the person responsible for the treatment (pharmacy) with such a code. Memantine and placebo (starch) were placed in the same capsules, and they were given to the patient as preprepared envelopes based on Codes 1 and 2.
The dose of memantine tablets for the first week was 10 mg a day, at 10:00 p.m., and for the second week was two tablets, at 8:00 a.m. and at 10:00 p.m., and placebo was similar to the memantine in the control group. Memantine tablet was provided by Sobhan-Drug Company in Iran.
The adult Conners' questionnaire was completed for participants before starting the treatment, third and sixth weeks, to determine the severity of ADHD symptoms. Subscale E shows the scale of the general level of symptoms associated with ADHD, and it is the best screen among the subscales for diagnosing people at risk. Using the appropriate normative table, the raw scores of each subscale are converted to T scores. T scores on this scale have a mean of 50 and a standard deviation of 10, and scores above 65 are clinically meaningful (Conners, Erhardt, & Sparrow, 1999) .
In this study, the Persian translation of the CAARS-S: S was used.
The pilot study was conducted on 20 samples, and its reliability was calculated using Cronbach's alpha method, which was equal to 0.81.
The contents of the study were evaluated by three child psychiatrists (Davari-Ashtiani, Jazayeri, Arabgol, Razjouyan, & Khademi, 2014).
The cut-off point for this questionnaire is 65, so that if a person has a score of 65 or higher, he/she has ADHD (Conners, Erhardt, & Sparrow, 1999) .
| K-SADS-PL
Semistructured diagnostic interview
This questionnaire is a semistructured diagnostic interview designed according to DSM-IV criteria and filled out by a psychiatrist during an interview with parents and child. The K-SADS-PL has good diagnostic capacity for mood, anxiety, behavior, and other psychiatric disorders. Ghanizadeh (2006) has reported the test-retest reliability of the Persian version of this questionnaire is 0.81, and the interrater reliability is 0.69 (Ghanizadeh, 2006) .
| Ethical considerations
1. Explanation of the units was involving in the research to maintain the confidentiality of the information. 
| Data analysis methods
Data were analyzed using SPSS-20 software. Repeated measure ANOVA was used for analyzing the effect of intervention at different times. Also, the mean of standard deviation was used for estimating descriptive purposes.
| RESULTS
The data of Table 1 show that the mean age in the intervention group was 34.7 ± 4.48, and 31.5 ± 7.49 in the control group. The number of men was more than that in women, and the number of married persons was the most, and the number of divorced persons was the least.
The results also showed that the number of unemployed and housekeeper individuals was the most in the two groups, and the number of individuals with academic degree was higher than that with elementary education in both groups. Table 1 shows that there were no significant differences (x 2 = 0, p ≥ 0.1), (x 2 = 0.47, p ≥ 0.49), (x 2 = 11.55, p ≥ 0.5), and (x 2 = 7.35, p ≥ 0.39) in gender, marital status, job, and education between groups of the study, respectively. Also, there was not significant differences (t = 10.63, p ≥ 0.10) between gender and groups of this study. Table 2 shows that there was a significant difference in Inattention/Memory Problems in the two groups during the times ( f = 14.07, p ≤ 0.001). Also, the results of this study showed that Hyperactivity/Restlessness had significant difference in two groups ( f = 14, p ≤ 0.001). The results of this study showed that Impulsivity/Emotional Lability in the two groups was significantly different ( f = 14, p ≤ 0.001). The results of this study indicated that Problems with Self-Concept in two groups per times were significantly different ( f = 4, p ≤ 0.001).
| DISCUSSION
ADHD is a behavioral disorder characterized by symptoms such as excessive restlessness and loss of attention and impulsivity (Chavez et al., 2009; Dopheide & Pliszka, 2009) . It is estimated that approximately 3% to 7% of children in school age, and approximately 4% of adults are infected with the disease (Polanczyk, De Lima, Horta, Biederman, & Rohde, 2007) .
The estimated ADHD prevalence in DSM-IV in the total sample was by 3.4%, significantly higher than the mean in France (7.3%, SE = 1.8), and in Colombia (1.9%, SE = 0.5), Lebanon (1.8%, SE = 0.7), Mexico (1.9%, SE = 0.4), and Spain (1.2%, SE = 0.6; Fayyad et al., 2007) .
Despite numerous drug therapies, introduction of alternative therapies is essential for various reasons, including side effects of drugs such as loss of appetite, sleep disorders, and mood problems (Polanczyk, De Lima, Horta, Biederman, & Rohde, 2007) . Various studies have shown that memantine is an effective medication for the treatment of ADHD (Biederman et al., 2017; Kotecha et al., 2002) .
The results of this study showed that there was no significant difference between two groups regarding age, sex, marital status, education level, occupational status, number of children, history of hyperactivity in the family, and underlying disease. Different studies have shown that there is no significant difference between the two groups in terms of age, sex, and type of ADHD (Adams et al., 2004 ; American Psychiatric Association, s, 1994).
There was no significant difference in Inattention/Memory Problems, Hyperactivity/Restlessness, Impulsivity/Emotional Lability between the two groups at baseline, but there was a significant difference in the third and sixth weeks. Also, in the repeated measurement analysis, there was a significant difference in the effect of drug and placebo changes (Inattention/Memory Problems, Impulsivity/Emotional Lability, Hyperactivity/Restlessness, Problems with Self-Concept and ADHD Index) between the two groups. In the study of Mohammadi, Mohammadzadeh, and Akhondzadeh (2015) , the behavior of the two groups was significantly different over time.
In the study carried out by Surman et al. (2013) , adult ADHD and ADHD NOS, aged 18-55, who received memantine up to 20 mg/day for 12 weeks showed a significant reduction in total symptoms, hyperactivity, and attention deficit, and with CGI rating scale, the rate of recovery was good and very good, and cognitive function of patients in attention deficit, working memory, and other dimensions of executive function was better in Weeks 6 and 12, respectively (Surman et al., 2013) . In this study, memantine was well stood, and severe side effects were not observed, but mild to moderate side effects were common and the medication was discontinued in six patients. Overall, in response to memantine treatment at the end of the course, the ADHD symptoms were improved in the subjects, and there was a significant difference between the two groups in terms of symptoms of restlessness and attention deficit (Surman et al., 2013) . In the study performed by Biederman et al. (2017) , improvement in the function of several neurological factors was observed in ADHD patients treated with memantine, although at the beginning of the study, this function was not anticipated (Biederman et al., 2017) . A remarkable point in the study of ADHD patients is that impulsiveness is the most serious aspect of ADHD through the lifetime of a person, which causes impairment in performance and makes treatment even more difficult, which reveals the importance of diagnosis and treatment (Bakhshani, Raghibi, & Babaei, 2011) .
The results of our study showed that the ADHD index and Inattention/Memory Problems in the two groups were not significantly different per baseline, but it was significant at the third and sixth weeks. Mohammadi et al. (2015) reported that there was a significant difference between the ADHD scores in the sixth week of treatment between the two groups, which is in agreement with the results of the present study. Moreover, Surman et al. (2013) reported that the ADHD score in sixth and 12th weeks was less than that in the first week of treatment with memantine. In a post hoc analysis, Reisberg et al. (2006) and Tariot et al. (2004) , in their pilot studies, have evaluated the effects of memantine on behavioral symptoms in patients with moderate to severe hyperactivity disorder, and they have observed positive and meaningful effect of the drug in patients treated with memantine. In general, the results of various studies have shown a positive effect of memantine on the treatment of ADHD (Surman et al., 2013) .
Based on the results of this study, memantine is tolerable and has low side effects in the samples. The results have shown that there was no significant difference in the side effects of the drug (dizziness, confusion, constipation, back pain, and sleepiness) at Weeks 1, 3, and 6 between two groups, but the mean of systolic and diastolic blood pressure was different between two groups. In the study of Mohammadi et al. (2015) , the most common adverse events associated with memantine were loss of appetite, headache, vomiting, nausea, and fatigue. In the study of Surman et al. (2013) , the most common complications in more than 10% of subjects were dizziness, digestive, muscle skeletal problems, and headache. In 2007, an openlabel study was carried out on 6-to 12-year-old patients with ADHD who were receiving memantine in two groups for 8 weeks. None of the patients with drug complications, death, or suicide was diagnosed.
Complications were mild, and more severe during the first week of treatment (Findling et al., 2007) . In the study of Sani et al., the most common side effects of memantine in adults were dizziness, constipation, headache, hypertension, and drowsiness (Hosenbocus & Chahal, 2013) . In general, adverse effects of memantine may be due to the unknown effect of NMDA antagonistic receptors on the proper functioning of memory and memory impairment (Bleich, Römer, Wiltfang, & Kornhuber, 2003; Rammsayer, 2006) .
| CONCLUSION
Based on the results of this study, it seems that memantine is effective in the treatment of adults with ADHD, and its side effects are mild and tolerable, although it seems that further studies are needed for evaluation of these effects.
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